prohibited list raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-03 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
==== UV-vis spectroscopy ==== Operando UV-vis spectroscopy is particularly useful for many homogeneous catalytic reactions because organometallic species are often colored. Fiber-optical sensors allow monitoring of the consumption of reactants and production of product within the solution through absorption spectra. Gas consumption as well as pH and electrical conductivity can also be measured using fiber-optic sensors within an operando apparatus.
Pinoline has also been reported to produce anxiogenic-like effects in rodents, which theoretically might be mediated by agonism of serotonin 5-HT2C receptors. In addition, it has been reported to produce antidepressant-like effects in rodents.
24494Pu + 4820Ca → 292114* → 290114 + 2 n + e− → 290113 + νe ? A single atom was observed which was thought to be the isotope 289114: the results were published in January 1999. Despite numerous attempts to repeat this reaction, an isotope with these decay properties has never again been found, and the exact identity of this activity is unknown. A 2016 paper by Sigurd Hofmann et al. considered that the most likely explanation of the 1998 result is that two neutrons were emitted by the produced compound nucleus, leading to 290114 and electron capture to 290113, while more neutrons were emitted in all other produced chains. This would have been the first report of a decay chain from an isotope of element 113, but it was not recognised at the time, and the assignment is still uncertain. A similar long-lived activity observed by the JINR team in March 1999 in the 242Pu + 48Ca reaction may be due to the electron-capture daughter of 287114, 287113; this assignment is also tentative.
== Preparation == The dessert is commonly made by taking a scoop of ice cream frozen well below the temperature at which ice cream is generally kept, possibly coating it in raw egg, rolling it in cornflakes or cookie crumbs, and briefly deep frying it. The extremely low temperature of the ice cream prevents it from melting while being fried. It may be sprinkled with cinnamon and sugar and a touch of peppermint; whipped cream or honey may be used, as well.
Sources: en.wikipedia.org
where Ntotal is the constant number of particles throughout the decay process, which is equal to the initial number of A nuclides since this is the initial substance. If the number of non-decayed A nuclei is:
Industrial production of ethoxylates is realized by a direct reaction of higher alcohols, acids, or amines with ethylene oxide in the presence of an alkaline catalyst at a temperature of 120–180 °C (250–360 °F). Modern plants producing ethoxylates are usually based on the BUSS LOOP reactors technology, which is based on a three-stage continuous process. In the first stage, the initiator or catalyst of the reaction and the feedstock are fed into the container, where they are mixed, heated, and vacuum dried. Then reaction is carried out in a special insulated reactor in an inert atmosphere (nitrogen) to prevent a possible explosion of ethylene oxide. Finally, the reaction mixture is neutralized, degassed, and purified.
JTT (1992). Published in the same year as BLOSOM, it also performs clustering and uses an implicit model. This may help reduce the systematic error from maximum parismony (MP), but also wastes sequence information. VTML (2001), a PAM-like matrix based on the alignments in the SYSTERS database, iteratively improved using a maximum likelihood estimator starting from the 1970s Dayhoff PAM model. WAG (Wheelan And Goldman, 2001) uses a maximum likelihood estimating procedure instead of any form of MP over a "BRKALN" dataset. The substitution scores are calculated based on the likelihood of a change considering multiple tree topologies derived using neighbor-joining. The scores correspond to a substitution model which includes also amino-acid stationary frequencies and a scaling factor in the similarity scoring. There are two versions of the matrix: WAG matrix based on the assumption of the same amino-acid stationary frequencies across all the compared protein and WAG* matrix with different frequencies for each of included protein families. PMB (Probability Matrix from Blocks, 2003), a set of "true" substitution frequencies estimated from the observed frequencies of BLOSUM, taking into account the possibility of a later substitution masking a previous one. It thus creates a evolutionary model where the distances have theoretical meaning (BLOSUM does not have this feature, unlike PAM, WAG, and most other later matrices, and hence is not recommended for phylogeny by IQ-TREE). LG (2008), which uses a larger dataset (Pfam-based) than WAG.
=== 2006–2010 === On November 2, 2006, NHK demonstrated a live relay of a UHDTV program over a 260 kilometer distance by a fiber-optic network. Using dense wavelength division multiplex (DWDM), 24 Gbit/s speed was achieved with a total of 16 different wavelength signals. On December 31, 2006, NHK demonstrated a live relay of their annual Kōhaku Uta Gassen over IP from Tokyo to a 450 inches (11 m) screen in Osaka. Using a codec developed by NHK, the video was compressed from 24 Gbit/s to 180–600 Mbit/s and the audio was compressed from 28 Mbit/s to 7–28 Mbit/s. Uncompressed, a 20-minute broadcast would require roughly 4 TB of storage. The SMPTE first released Standard 2036 for UHDTV in 2007. UHDTV was defined as having two levels, called UHDTV1 (3840 × 2160) and UHDTV2 (7680 × 4320). In May 2007, the NHK did an indoor demonstration at the NHK Open House in which a UHDTV signal (7680 × 4320 at 60 fps) was compressed to a 250 Mbit/s MPEG2 stream. The signal was input to a 300 MHz wide band modulator and broadcast using a 500 MHz QPSK modulation. This "on the air" transmission had a very limited range (less than 2 meters), but shows the feasibility of a satellite transmission in the 36,000 km orbit. In 2008, Aptina Imaging announced the introduction of a new CMOS image sensor specifically designed for the NHK UHDTV project. During IBC 2008 Japan's NHK, Italy's RAI, BSkyB, Sony, Samsung, Panasonic Corporation, Sharp Corporation, and Toshiba (with various partners) demonstrated the first ever public live transmission of UHDTV, from London to the conference site in Amsterdam.
==== MeSH D12.125.740 – phosphoamino acids ==== MeSH D12.125.740.025 – 2-amino-5-phosphonovalerate MeSH D12.125.740.675 – phosphocreatine MeSH D12.125.740.700 – phosphoserine MeSH D12.125.740.725 – phosphothreonine MeSH D12.125.740.740 – phosphotyrosine
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.